Search Results - "DIPPEL, E."

Refine Results
  1. 1

    Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature by Stranzenbach, R., Dippel, E., Schlaak, M., Stadler, R.

    Published in British journal of dermatology (1951) (01-12-2017)
    “…Summary Brentuximab vedotin is an antibody–drug conjugate that brings the antimicrotubule agent monomethyl auristatin E into CD30‐expressing cells. Some prior…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Prospective evaluation of follow-up in melanoma patients in Germany – Results of a multicentre and longitudinal study by Livingstone, E, Krajewski, C, Eigentler, T.K, Windemuth-Kieselbach, C, Benson, S, Elsenbruch, S, Hauschild, A, Rompel, R, Meiss, F, Mauerer, A, Kähler, K.C, Dippel, E, Möllenhoff, K, Kilian, K, Mohr, P, Utikal, J, Schadendorf, D

    Published in European journal of cancer (1990) (01-03-2015)
    “…Abstract Background Patient numbers requiring long-term melanoma surveillance are constantly rising. Surveillance is costly and guideline recommendations vary…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3 by Booken, N, Gratchev, A, Utikal, J, Weiß, C, Yu, X, Qadoumi, M, Schmuth, M, Sepp, N, Nashan, D, Rass, K, Tüting, T, Assaf, C, Dippel, E, Stadler, R, Klemke, C-D, Goerdt, S

    Published in Leukemia (01-02-2008)
    “…Sezary syndrome (SS) is a rare, aggressive CD4 + cutaneous T-cell lymphoma (CTCL); molecular traits differentiating SS from nonleukemic mycosis fungoides (MF)…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells by Felcht, M., Heck, M., Weiss, C., Becker, J.C., Dippel, E., Müller, C.S.L., Nashan, D., Sachse, M.M., Nicolay, J.P., Booken, N., Goerdt, S., Klemke, C.-D.

    Published in British journal of dermatology (1951) (01-08-2012)
    “…Summary Background  Primary cutaneous B‐cell lymphomas (PCBCL) are subdivided into the aggressive form, primary cutaneous diffuse large B‐cell lymphoma, leg…”
    Get full text
    Journal Article
  9. 9

    Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome by Klemke, C-D., Mansmann, U., Poenitz, N., Dippel, E., Goerdt, S.

    Published in British journal of dermatology (1951) (01-07-2005)
    “…Summary Background  Cutaneous T‐cell lymphoma (CTCL) is a slowly progressive malignancy for which there is no cure. Therefore, accurate prediction of prognosis…”
    Get full text
    Journal Article
  10. 10

    T cell receptor γδ bearing cells are decreased in the peripheral blood of patients with atopic diseases by SCHAUER, U., DIPPEL, E., GIELER, U., BRÄUER, J., JUNG, T., HEYMANNS, J., RIEGER, C. H. L.

    Published in Clinical and experimental immunology (28-06-2008)
    “…SUMMARY The biological role of T cell receptor (TCR) γδ bearing cells is currently not fully understood. Recently, a monoclonal antibody (TCRδ1) reacting…”
    Get full text
    Journal Article
  11. 11

    Dose-dependent severe cutaneous reactions to imatinib by UGUREL, S, HILDENBRAND, R, DIPPER, E, HOCHHAUS, A, SCHADENDORF, D

    Published in British journal of cancer (22-04-2003)
    “…The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of…”
    Get full text
    Journal Article
  12. 12

    Atypical fibroxanthoma and pleomorphic dermal sarcoma by Ziemer, M, Jäger, I M, Dippel, E

    Published in Hautarzt (01-09-2019)
    “…Atypical fibroxanthoma (AFX) or undifferentiated pleomorphic sarcoma (UPS) is a rare malignant neoplastic disease of the skin. At the beginning of the 1960s…”
    Get full text
    Journal Article
  13. 13

    Cylindromas-rare but striking by Löser, C, Rütten, A, Dippel, E

    Published in Hautarzt (01-09-2019)
    “…Cylindromas are rare tumors of adnexal structures in adults. They are predominantly found on the scalp and face. More impressive than incidentally diagnosed…”
    Get full text
    Journal Article
  14. 14

    Cutaneous large B‐cell lymphoma of the leg masquerading 
as a chronic venous ulcer by Garbea, A., Dippel, E., Hildenbrand, R., Bleyl, U., Schadendorf, D., Goerdt, S.

    Published in British journal of dermatology (1951) (01-01-2002)
    “…Summary We report on a 74‐year‐old female patient with a primary cutaneous CD20+, diffuse large cell B‐cell lymphoma of the lower leg resembling a chronic…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Chirurgische Therapie des malignen Melanoms by Dippel, E., Schmitt, L., Merkel, S., Göhl, J.

    Published in Der Onkologe (01-06-2014)
    “…Zusammenfassung Hintergrund Die zunehmende Inzidenz sowie eine Verbesserung im Gesamtüberleben führen weltweit zu einer steigenden Prävalenz von Patienten mit…”
    Get full text
    Journal Article
  17. 17
  18. 18

    A Heterotrimeric G Protein Complex Couples the Muscarinic m1 Receptor to Phospholipase C-β by Dippel, Edgar, Kalkbrenner, Frank, Wittig, Burghardt, Schultz, Günter

    “…We addressed the question as to which subtypes of G protein subunits mediate the activation of phospholipase C-β by the muscarinic m1 receptor. We used the rat…”
    Get full text
    Journal Article
  19. 19

    Systemic treatment of distant metastatic malignant melanoma by Dabrowski, E, Dippel, E

    Published in Radiologe (01-02-2015)
    “…Systemic therapy of advanced metastatic malignant melanoma has been considerably changed by the approval of new drugs in recent years. The targeted therapy…”
    Get full text
    Journal Article
  20. 20

    Jessner's lymphocytic infiltration of the skin: a CD8+ polyclonal reactive skin condition by Poenitz, N, Dippel, E, Klemke, C-D, Qadoumi, M, Goerdt, S

    Published in Dermatology (Basel) (01-01-2003)
    “…Jessner's lymphocytic infiltration of the skin (JLIS) is a clinically and histologically distinct disease entity. Conflicting results have been reported…”
    Get more information
    Journal Article